Form 4 · Statement of Changes in Beneficial Ownership · Filed 2025-11-26
Kramer Kelly A. Files Gilead Sciences (GILD) Form 4 - November 26, 2025
Kramer Kelly A. traded 11.2K GILD shares worth $1.2M in this Form 4 filing, reported to the SEC on 2025-11-26.
- Insider
- Kramer Kelly A.
- Issuer
- Gilead Sciences Inc. GILD · NASDAQ
- Filed
- Period
- 2025-11-26
- Accession
- 0001629885-25-000005
- Source
- Official filing on sec.gov ↗
Transactions (4)
| Insider | Date | Type | Shares | Price | Value | Own |
|---|---|---|---|---|---|---|
| Kramer Kelly A. | 2025-11-28 | Buy | 2.8K | $81.00 | $227.2K | Direct |
| Kramer Kelly A. | 2025-11-28 | Sell | 2.8K | $127.10 | $356.5K | Direct |
| Kramer Kelly A. | 2025-11-26 | Buy | 2.8K | $81.00 | $227.3K | Direct |
| Kramer Kelly A. | 2025-11-26 | Sell | 2.8K | $127.11 | $356.7K | Direct |
| Net change | 0 | −$258.7K | ||||
About Gilead Sciences Inc.
Gilead Sciences Inc. is a biopharmaceutical company that focuses on researching, developing, and commercializing innovative medicines in areas of unmet medical need. It is globally recognized for its distinguished work, particularly in the treatment of HIV, liver diseases such as hepatitis B and C, and various forms of cancer. The company's portfolio includes groundbreaking antiviral therapies and a robust pipeline of investigational drugs. Headquartered in Foster City, California, Gilead Sciences Inc. significantly contributes to the healthcare sector by extending the lives of patients with serious illnesses worldwide. Through strategic partnerships and continuous innovation, Gilead remains at the forefront of modern medicine, enhancing its role in the global pharmaceutical market.
Track GILD insider activity
Get alerted when Gilead Sciences Inc. executives buy or sell their shares.